← Eichor
Study identifier: NCT04342546 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction

Condition: Breast Cancer · Capsular Contracture Associated With Breast Implant  ·  Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

PhaseNA
Planned participants250
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study evaluates the capacity of the NovaGray RILA Breast® test to predict the toxicity linked to radiotherapy and the impact of implant breast reconstruction.

This description comes directly from the study's public registry record.

Talk to the study team

Aurore MOUSSION  ·  04 67 61 31 02  ·  DRCI-icm105@icm.unicancer.fr

Emmanuelle TEXIER  ·  04 67 61 31 02  ·  DRCI-icm105@icm.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (9)

Centre Georges François LeclercDijon, FranceRecruiting
Centre Oscar LambretLille, FranceRecruiting
Centre Léon BérardLyon, FranceRecruiting
Institut Paoli CalmetteMarseille, FranceRecruiting
Institut du Cancer de MontpellierMontpellier, FranceRecruiting
centre Antoine LacassagneNice, FranceRecruiting
Hôpital TenonParis, FranceRecruiting
Institut de Cancérologie de l'OuestSaint-Herblain, FranceRecruiting
Institut Claudius RegaudToulouse, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04342546